IDH1 and acute myeloid leukemia: The antileukemic effect of dasatinib was confirmed in an in vivo mouse model of IDH1-wt/-mut KG1a and also observed in a single patient with IDH1-mut AML, supporting dasatinib as potential treatment option for IDH1-mut AML.